Skip to main content

Table 4 p53 status and prognosis of colorectal cancer: past literature date

From: Does anti-p53 antibody status predict for clinical outcomes in metastatic colorectal cancer patients treated with fluoropyrimidine, oxaliplatin, plus bevacizumab as first-line chemotherapy?

Reference

n

Histology treatment

Methods for determing p53 Ab

IHC

Sequencing

Frequency alterd p53 pathway (%)

Prognostic value

Overall survial

Survival

Response

LAN YT [10]

258

ACC

surgery

-

+

-

37.6(IHC)

univariate

NA

NA

Triantafyllou K [11]

55

Adenoma

Polypectomy

-

+

-

41.8DtHCD

NA

murtivariate

NA

Wang Q [12]

40

ACC

surgery

-

+

-

65 OHCD

univariate

NA

NA

Hu J [13]

120

ACC

biopsy and surgery

-

+

-

57 OHCD

univariate

NA

NA

Grewal H [14]

66

ACC

surgery

-

+

-

51.5(IHC)

NS

NA

NA

Bouzourenne H [15]

122

ACC

surgery

-

+

+

47(IHC)

univariate

NA

NA

32(S)

murtivariate

Samowitz WS [16]

1464

ACC

biopsy and surgery

-

-

+

45.4DSD

univariate

NA

NA

Chang SC [17]

167

ACC

surgery

+

-

+

28.1(Ab)

univariate

NA

NA

56.3(S)

murtivariate

Angelopoulou K [18] 229

ACC

biopsy and surgery

+

-

-

23(Ab)

NS

NS

NA

Kressner U [19]

184

ACC

surgery

+

-

-

32(Ab)

univariate

NA

NA

Suppiah A [20]

28

ACC

surgery

+

-

-

21,7(Ab)

NS

NS

NA

Kreessner U [21]

294

ACC

biopsy

+

-

-

55DAbD

NS

NA

NA

  1. Ab antibody; IHC immunohistochemistry; S sequencing; ACC advanced colorectal cancer; NA not available; NS not significant